This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoGenomics Appoints Dr. Barbara Chaitin As Director Of Surgical Pathology And Medical Director For Its Florida Lab









FT. MYERS, Fla., Jan. 4, 2012 /PRNewswire/ --  NeoGenomics, Inc. (NASD OTC BB: NGNM), a leading provider of cancer-focused genetic testing services, announced today the appointment of Dr. Barbara Chaitin as Director of Surgical Pathology for NeoGenomics Laboratories and Medical Director of the Fort Myers, Florida laboratory. 

Dr. Chaitin was recently the Director of Esoteric Services, and Chair of the Solid Tumor Committee, at AmeriPath, a division of Quest Diagnostics Inc.  Prior to that time, she was National Medical Director and Head of Solid Tumor Services at Genzyme Genetics in New York City.  Dr. Chaitin's professional experience also includes service as Associate Medical Director at IMPATH Laboratories in New York City and Bender Laboratory in Albany, New York.  Early in her career, she served as a Forensic Pathologist for New York State, and as an Attending Pathologist and Assistant Professor of Pathology at New York University Medical School and Albert Einstein College of Medicine.

Dr. Chaitin attended Albert Einstein College of Medicine, completed her Anatomic and Clinical Pathology Residency at University of California in San Francisco, and completed Fellowships in Surgical Pathology at Stanford University Medical Center and at MD Anderson Cancer Center.  She is Board certified in both Forensic Pathology and Anatomic Pathology. 

Doug VanOort, NeoGenomics Chairman and CEO commented, "Dr. Chaitin brings a wealth of experience and valuable expertise to NeoGenomics.  We have strong expertise in the application of molecular genetics in oncology and hematology, and our clients are requesting that we continue to enhance our capabilities for solid tumor pathways and disease.  We are looking forward to Dr. Chaitin's medical leadership as we expand our immunohistochemistry offering and introduce new FISH and molecular tests targeted at solid tumor pathology.  We are excited to welcome Dr. Chaitin to our Medical Team and to our company."



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs